The 6-Figure Options Bet on Soaring Array Biopharma Inc (ARRY)

M&A rumors have Array Biopharma Inc (ARRY) charging up the charts

Jan 13, 2017 at 2:06 PM
facebook X logo linkedin

Array Biopharma Inc (NASDAQ:ARRY) has had an exciting week, with buyout buzz fueling an earlier rally, which put the shares above a key retracement level. Today more unconfirmed M&A rumors seem to be swirling as ARRY soars 9.7% to $11.09 amid heavy volume, and earlier tapped a new nine-year high of $11.15. Meanwhile, one options trader placed a sizable bet, expecting the drug stock's ascent to stall.

Jumping right in, ARRY's call options are crossing the tape at 16 times the typical intraday pace, with call volume running in the 99th percentile of its annual range. Accounting for the bulk of this action is the March 12 call, where a sweep of 5,500 contracts was sold to open this morning, according to Trade-Alert. The call writer's goal is for ARRY to remain below the $12 mark through the option's expiration, on Friday, March 17. And by selling the calls, this trader pocketed a premium of over $412,000 (5,500 contracts * 100 shares per contract * $0.75 apiece).

Taking a step back, call-heavy action is nothing new for ARRY, though absolute volumes tend to be light. Specifically, the stock has seen more than 1,000 calls bought to open over the past 10 days at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), compared to just 47 puts. But call selling is even more popular, with nearly 5,100 ARRY calls sold to open over the same period.

Outside of the options pits, sentiment toward the biotech stock is rather upbeat. All nine analysts tracking the stock maintain the equivalent of a "strong buy" rating -- though today's climb has left the average 12-month price target of $10.13 sitting underfoot. And though short interest accounts for 10.7% of ARRY's total float, these bearish bets are also seated close to their lowest level since April 2014.

Given the stock's technical prowess, it seems unlikely bulls will lose faith anytime soon, unless the takeover talk gets shut down. Array Biopharma Inc (NASDAQ:ARRY) is sitting on a whopping 231% year-over-year lead, and is on track to close today above the $11 mark for the first time since late 2007.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI